These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 20493398)

  • 1. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
    Gaspar HB
    Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
    Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
    Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
    Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
    Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
    Taupin P
    IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).
    Kohn DB; Gaspar HB
    J Clin Immunol; 2017 May; 37(4):351-356. PubMed ID: 28194615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
    Ferrua F; Aiuti A
    Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency.
    Serana F; Sottini A; Chiarini M; Zanotti C; Ghidini C; Lanfranchi A; Notarangelo LD; Caimi L; Imberti L
    J Immunol; 2010 Dec; 185(12):7713-22. PubMed ID: 21057082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.
    Bradford KL; Moretti FA; Carbonaro-Sarracino DA; Gaspar HB; Kohn DB
    J Clin Immunol; 2017 Oct; 37(7):626-637. PubMed ID: 28842866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.
    Kohn DB; Hershfield MS; Puck JM; Aiuti A; Blincoe A; Gaspar HB; Notarangelo LD; Grunebaum E
    J Allergy Clin Immunol; 2019 Mar; 143(3):852-863. PubMed ID: 30194989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
    Sauer AV; Brigida I; Carriglio N; Hernandez RJ; Scaramuzza S; Clavenna D; Sanvito F; Poliani PL; Gagliani N; Carlucci F; Tabucchi A; Roncarolo MG; Traggiai E; Villa A; Aiuti A
    Blood; 2012 Feb; 119(6):1428-39. PubMed ID: 22184407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.
    Scott O; Kim VH; Reid B; Pham-Huy A; Atkinson AR; Aiuti A; Grunebaum E
    J Clin Immunol; 2017 Aug; 37(6):582-591. PubMed ID: 28748310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for adenosine deaminase severe combined immune deficiency-An unexpected journey of four decades.
    Kohn DB
    Immunol Rev; 2024 Mar; 322(1):148-156. PubMed ID: 38033164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
    Silver JN; Flotte TR
    Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.
    Aiuti A; Brigida I; Ferrua F; Cappelli B; Chiesa R; Marktel S; Roncarolo MG
    Immunol Res; 2009; 44(1-3):150-9. PubMed ID: 19224139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.
    Tartibi HM; Hershfield MS; Bahna SL
    Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26684479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients with severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency by autologous transplantation of genetically modified bone marrow cells.
    Hoogerbrugge PM; Vossen JM; v Beusechem VW; Valerio D
    Hum Gene Ther; 1992 Oct; 3(5):553-8. PubMed ID: 1420454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.